Table 4.
Adverse events
| Rituximab, no cyclophosphamide (n = 20) | Rituximab + cyclophosphamide (n = 100) | P value | |
|---|---|---|---|
| Incidence of relapse (per person-year) 95% CI | 0.22 (0.14, 0.31) | 0.21 (0.18, 0.24) | 0.89 |
| Incidence of infection (per person-year) 95% CI | 0.21 (0.15, 0.28) | 0.13 (0.12, 0.15) | 0.08 |
| Incidence of severe infection (per person-year) 95% CI | 0.12 (0.08, 0.24) | 0.17 (0.13, 0.22) | 0.63 |
| Cancera, n (%) | 0 | 18 (18%) | 0.04 |
| MI, n (%) | 0 | 0 | 0.99 |
| CVA, n (%) | 0 | 1 (1%) | 0.99 |
| ESKD, n (%) | 1 (5%) | 9 (9%) | 0.99 |
| Death, n (%) | 1 (5%) | 7 (7%) | 0.99 |
| ESKD or death (%) | 1 (5%) | 14 (14%) | 0.46 |
*P values were calculated by Fisher's exact test for categorical variables and Wilcoxon two-sample test for continuous variables.
CI, confidence interval; MI, myocardial infarction; CVA, cerebrovascular accident, ESKD, end-stage kidney disease.
aIncludes non-melanoma skin cancers.